Incannex Healthcare Inc. (IXHL) announced on October 22, 2025 that the Nasdaq Stock Market has granted the company a 180‑day extension to regain compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The extension extends the deadline to April 20, 2026, giving the company a defined period to bring its closing bid price to at least US$1.00 for ten consecutive business days.
The Nasdaq decision was made after the company demonstrated that it meets all other listing criteria, including market value of publicly held shares, and provided written notice of its intention to cure the deficiency. Incannex indicated it may pursue a reverse stock split or other actions to raise the share price and maintain compliance with the bid‑price rule.
CEO Joel Latham said the extension “provides Incannex with continued flexibility as we advance our operational and strategic objectives.” He added that the company’s strong cash position and robust pipeline of combination therapies position it well to execute on its strategy and drive long‑term value for shareholders.
The extension gives Incannex a clear timeline to address the bid‑price deficiency and avoid potential delisting, thereby preserving market access and investor confidence.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.